Acute severe ulcerative colitis: efficacy and safety of JAK inhibitors - PubMed
4 hours ago
- #JAK inhibitors
- #ulcerative colitis
- #treatment efficacy
- Acute severe ulcerative colitis is a life-threatening condition requiring hospitalization and prompt intervention.
- Corticosteroids are the initial therapy, but 30-40% of patients have steroid-refractory disease, needing rescue treatments like infliximab or cyclosporine.
- Janus kinase inhibitors (e.g., tofacitinib, upadacitinib, filgotinib) offer rapid onset and oral administration as new therapeutic options.
- Studies, including retrospective research and one randomized controlled trial, suggest JAK inhibitors can induce clinical response and reduce colectomy rates.
- Although safety concerns exist, current evidence indicates an acceptable safety profile for JAK inhibitors.